PE20180174A1 - Nuevos epitopos celulares y nuevas combinaciones de epitopos celulares para el uso en la inmunoterapia del mieloma y de otros tipos de cancer - Google Patents
Nuevos epitopos celulares y nuevas combinaciones de epitopos celulares para el uso en la inmunoterapia del mieloma y de otros tipos de cancerInfo
- Publication number
- PE20180174A1 PE20180174A1 PE2017002495A PE2017002495A PE20180174A1 PE 20180174 A1 PE20180174 A1 PE 20180174A1 PE 2017002495 A PE2017002495 A PE 2017002495A PE 2017002495 A PE2017002495 A PE 2017002495A PE 20180174 A1 PE20180174 A1 PE 20180174A1
- Authority
- PE
- Peru
- Prior art keywords
- cellular
- new
- peptides
- myeloma
- relates
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 206010035226 Plasma cell myeloma Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 201000000050 myeloid neoplasm Diseases 0.000 title abstract 2
- 230000001413 cellular effect Effects 0.000 title 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 2
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000005975 antitumor immune response Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
Abstract
La presente invencion se refiere a peptidos, proteinas, acidos nucleicos y celulas destinados a la utilizacion en metodos inmunoterapeuticos. En particular, la presente invencion se refiere a la inmunoterapia contra el cancer, en particular del mieloma. La presente invencion se refiere asimismo a epitopos peptidicos para linfocitos T asociados a tumores, solos o en combinacion con otros peptidos asociados a tumores que, por ejemplo, pueden servir como principios activos farmaceuticos en composiciones vacunales destinadas a estimular respuestas inmunitarias antitumorales, o a estimular ex vivo linfocitos T que despues seran transferidos a los pacientes. Los peptidos unidos a moleculas del complejo mayor de histocompatibilidad (MHC), o los peptidos como tales, tambien pueden ser dianas de anticuerpos, de receptores de linfocitos T solubles, y de otras moleculas de union
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562184500P | 2015-06-25 | 2015-06-25 | |
GBGB1511191.7A GB201511191D0 (en) | 2015-06-25 | 2015-06-25 | T-cell epitopes for the immunotherapy of myeloma |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20180174A1 true PE20180174A1 (es) | 2018-01-22 |
Family
ID=53872214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2017002495A PE20180174A1 (es) | 2015-06-25 | 2016-06-21 | Nuevos epitopos celulares y nuevas combinaciones de epitopos celulares para el uso en la inmunoterapia del mieloma y de otros tipos de cancer |
Country Status (18)
Country | Link |
---|---|
US (2) | US10196422B2 (es) |
EP (1) | EP3313860A2 (es) |
JP (1) | JP2018520653A (es) |
KR (1) | KR20180012865A (es) |
CN (1) | CN107889489A (es) |
AU (1) | AU2016284857A1 (es) |
BR (1) | BR112017027639A2 (es) |
CA (1) | CA2990507A1 (es) |
CR (1) | CR20180051A (es) |
EA (1) | EA201792484A1 (es) |
GB (1) | GB201511191D0 (es) |
IL (1) | IL255932A (es) |
MA (5) | MA46506A1 (es) |
MX (1) | MX2017016207A (es) |
PE (1) | PE20180174A1 (es) |
SG (1) | SG10202001488VA (es) |
TW (1) | TW201710289A (es) |
WO (1) | WO2016207164A2 (es) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
WO2015095811A2 (en) | 2013-12-20 | 2015-06-25 | The Board Institute Inc. | Combination therapy with neoantigen vaccine |
US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
CN108604257B (zh) * | 2015-10-12 | 2022-12-13 | 南托米克斯有限责任公司 | 产生特异性免疫治疗组合物及其相关核酸构建体的方法 |
ES2970865T3 (es) | 2015-12-16 | 2024-05-31 | Gritstone Bio Inc | Identificación, fabricación y uso de neoantígenos |
KR20180107257A (ko) | 2016-02-19 | 2018-10-01 | 난트 홀딩스 아이피, 엘엘씨 | 면역원 조절 방법 (methods of immunogenic modulation) |
JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
JP2019524773A (ja) * | 2016-08-02 | 2019-09-05 | ナントセル,インコーポレイテッド | 樹状細胞のトランスフェクション及びその方法 |
DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
CN110662556A (zh) * | 2017-03-09 | 2020-01-07 | 哈佛大学的校长及成员们 | 癌症疫苗 |
CA3059645A1 (en) | 2017-04-10 | 2018-10-18 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers |
EA201992416A1 (ru) | 2017-04-10 | 2020-02-25 | Имматикс Байотекнолоджиз Гмбх | Пептиды и комбинации пептидов для применения в иммунотерапии лейкозов и других видов рака |
WO2018224166A1 (en) * | 2017-06-09 | 2018-12-13 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy |
DE102017115966A1 (de) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Polypeptidmolekül mit verbesserter zweifacher Spezifität |
ES2871146T3 (es) | 2017-07-14 | 2021-10-28 | Immatics Biotechnologies Gmbh | Molécula de polipéptido con especificidad dual mejorada |
CN111465989B (zh) * | 2017-10-10 | 2024-06-25 | 磨石生物公司 | 使用热点进行的新抗原鉴别 |
CN111630602A (zh) | 2017-11-22 | 2020-09-04 | 磨石肿瘤生物技术公司 | 减少新抗原的接合表位呈递 |
DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
CN107937515B (zh) * | 2017-12-06 | 2018-11-09 | 北京泱深生物信息技术有限公司 | 一种阿尔茨海默的诊疗基因靶点及其应用 |
MA51792A (fr) | 2018-02-09 | 2020-12-16 | Immatics Us Inc | Procédés de fabrication de lymphocytes t |
TW202016131A (zh) * | 2018-05-16 | 2020-05-01 | 德商英麥提克生物技術股份有限公司 | 用於抗癌免疫治療的肽 |
TW202019955A (zh) | 2018-07-31 | 2020-06-01 | 德商英麥提克生物技術股份有限公司 | B*07 限制肽和肽組合的抗癌免疫治療和相關方法 |
BR112021003545A2 (pt) * | 2018-08-29 | 2021-05-18 | Amyris, Inc. | células e métodos para ensaio baseado em seleção |
EP3844172A4 (en) * | 2018-08-30 | 2022-08-10 | Université de Montréal | PROTEOGENOMICS-BASED PROCEDURE FOR IDENTIFICATION OF TUMOR-SPECIFIC ANTIGENS |
US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
WO2020243134A1 (en) | 2019-05-27 | 2020-12-03 | Immatics US, Inc. | Viral vectors and their use in adoptive cellular therapy |
AU2020286756A1 (en) | 2019-06-06 | 2022-01-27 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides |
KR20220025808A (ko) * | 2019-06-25 | 2022-03-03 | 유니버시떼 드 몬트리얼 | 난소암에 대한 신규한 종양-특이적인 항원 및 이의 용도 |
US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
US20210154280A1 (en) * | 2019-11-18 | 2021-05-27 | Epivax Oncology, Inc. | Neo-epitope vaccines and methods of treating cancer |
JP2023515131A (ja) | 2020-02-24 | 2023-04-12 | イマティクス ユーエス,アイエヌシー. | がんおよび関連する悪性腫瘍の治療のためにt細胞を増殖させる方法 |
DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
CA3177481A1 (en) | 2020-05-08 | 2021-11-11 | David R. Liu | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
KR102361479B1 (ko) * | 2020-06-18 | 2022-02-11 | 고려대학교 산학협력단 | siRNA의 생성 및 기능 증진 활성을 갖는 CMTR1의 신규용도 |
TW202227616A (zh) | 2020-08-21 | 2022-07-16 | 美商英麥提克斯股份有限公司 | 分離cd8+選擇t細胞的方法 |
EP4271481A2 (en) | 2020-12-31 | 2023-11-08 | Immatics US, Inc. | Cd8 polypeptides, compositions, and methods of using thereof |
KR20240004937A (ko) | 2021-05-05 | 2024-01-11 | 이매틱스 바이오테크놀로지스 게엠베하 | Bma031 항원 결합 폴리펩타이드 |
CN113476619B (zh) * | 2021-07-08 | 2022-11-29 | 上海交通大学医学院附属仁济医院 | 一种18f标记纳米抗体探针及其制备方法和应用 |
EP4392441A1 (en) | 2021-08-24 | 2024-07-03 | Immatics US, Inc. | Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange |
US20230089392A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
US20230348548A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
US20230348561A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
US20240066127A1 (en) | 2022-04-28 | 2024-02-29 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7368531B2 (en) * | 1997-03-07 | 2008-05-06 | Human Genome Sciences, Inc. | Human secreted proteins |
WO2003074567A2 (en) * | 2002-03-01 | 2003-09-12 | Immunomedics, Inc. | Internalizing anti-cd74 antibodies and methods of use |
DE10360456A1 (de) * | 2003-12-22 | 2005-07-28 | Vaecgene Biotech Gmbh | Tumorantigene und deren Verwendung |
EP2292796A1 (en) * | 2005-02-10 | 2011-03-09 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
EP1760089B1 (en) | 2005-09-05 | 2009-08-19 | Immatics Biotechnologies GmbH | Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine |
US20100009463A1 (en) * | 2006-07-13 | 2010-01-14 | Peter Hornbeck | Reagents for the detection of protein phosphorylation in signaling pathways |
NZ582822A (en) * | 2007-07-27 | 2012-06-29 | Immatics Biotechnologies Gmbh | Novel immunogenic epitopes for immunotherapy |
MX2010001088A (es) * | 2007-07-27 | 2010-06-01 | Immatics Biotechnologies Gmbh | Composicion de peptidos asociados a tumor y vacunas relacionadas contra el cancer. |
US20100209427A1 (en) * | 2008-09-24 | 2010-08-19 | Yu Li | Lysine acetylation sites |
WO2011119484A1 (en) * | 2010-03-23 | 2011-09-29 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
GB201009222D0 (en) | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
WO2014082729A1 (en) * | 2012-11-28 | 2014-06-05 | Biontech Ag | Individualized vaccines for cancer |
WO2014200910A2 (en) * | 2013-06-10 | 2014-12-18 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
-
2015
- 2015-06-25 GB GBGB1511191.7A patent/GB201511191D0/en not_active Ceased
-
2016
- 2016-06-16 TW TW105118858A patent/TW201710289A/zh unknown
- 2016-06-21 AU AU2016284857A patent/AU2016284857A1/en not_active Abandoned
- 2016-06-21 MA MA46506A patent/MA46506A1/fr unknown
- 2016-06-21 EP EP16732263.5A patent/EP3313860A2/en not_active Withdrawn
- 2016-06-21 CN CN201680037125.9A patent/CN107889489A/zh active Pending
- 2016-06-21 BR BR112017027639A patent/BR112017027639A2/pt not_active Application Discontinuation
- 2016-06-21 EA EA201792484A patent/EA201792484A1/ru unknown
- 2016-06-21 MA MA46504A patent/MA46504A1/fr unknown
- 2016-06-21 CR CR20180051A patent/CR20180051A/es unknown
- 2016-06-21 MX MX2017016207A patent/MX2017016207A/es unknown
- 2016-06-21 CA CA2990507A patent/CA2990507A1/en not_active Abandoned
- 2016-06-21 PE PE2017002495A patent/PE20180174A1/es unknown
- 2016-06-21 KR KR1020187001628A patent/KR20180012865A/ko unknown
- 2016-06-21 WO PCT/EP2016/064317 patent/WO2016207164A2/en active Application Filing
- 2016-06-21 JP JP2017560907A patent/JP2018520653A/ja active Pending
- 2016-06-21 MA MA46508A patent/MA46508A1/fr unknown
- 2016-06-21 SG SG10202001488VA patent/SG10202001488VA/en unknown
- 2016-06-21 MA MA46507A patent/MA46507A1/fr unknown
- 2016-06-21 MA MA41521A patent/MA41521A1/fr unknown
- 2016-06-24 US US15/191,895 patent/US10196422B2/en active Active
-
2017
- 2017-11-26 IL IL255932A patent/IL255932A/en unknown
-
2018
- 2018-11-20 US US16/196,812 patent/US10377797B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
MA46507A1 (fr) | 2021-03-31 |
US10196422B2 (en) | 2019-02-05 |
MA46504A1 (fr) | 2021-03-31 |
WO2016207164A2 (en) | 2016-12-29 |
EA201792484A1 (ru) | 2018-05-31 |
MA41521A1 (fr) | 2018-06-29 |
IL255932A (en) | 2018-01-31 |
MA46508A1 (fr) | 2021-09-30 |
GB201511191D0 (en) | 2015-08-12 |
CA2990507A1 (en) | 2016-12-29 |
EP3313860A2 (en) | 2018-05-02 |
MA46506A1 (fr) | 2021-03-31 |
MX2017016207A (es) | 2018-07-06 |
SG10202001488VA (en) | 2020-04-29 |
AU2016284857A1 (en) | 2017-12-07 |
JP2018520653A (ja) | 2018-08-02 |
US20190077832A1 (en) | 2019-03-14 |
WO2016207164A3 (en) | 2017-02-02 |
CN107889489A (zh) | 2018-04-06 |
CR20180051A (es) | 2018-05-25 |
TW201710289A (zh) | 2017-03-16 |
KR20180012865A (ko) | 2018-02-06 |
BR112017027639A2 (pt) | 2018-09-11 |
US10377797B2 (en) | 2019-08-13 |
US20170022251A1 (en) | 2017-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20180174A1 (es) | Nuevos epitopos celulares y nuevas combinaciones de epitopos celulares para el uso en la inmunoterapia del mieloma y de otros tipos de cancer | |
AR127117A2 (es) | Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores | |
CO2018002202A2 (es) | Péptidos y combinaciones de péptidos para inmunoterapia contra el cáncer de próstata y otros tipos de cáncer | |
CL2023001346A1 (es) | Uso de péptidos en inmunoterapia contra cáncer de pulmón amicrocítico y otros. | |
CL2018000780A1 (es) | Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer microcítico de pulmón y otros tipos de cáncer | |
PE20181164A1 (es) | Nuevos peptidos, combinaciones de peptidos y soportes para el uso en el tratamiento inmunoterapeutico de varios tipos de cancer | |
CO2018000252A2 (es) | Péptidos y combinaciones de péptidos para inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer | |
CO2018008763A2 (es) | Péptidos, combinaciones de péptidos y células para el uso en la inmunoterapia contra el cáncer de vejiga urinaria y otros tipos de cáncer | |
CO2018003860A2 (es) | Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer de mama y otros tipos de cáncer | |
CO2017008902A2 (es) | Péptidos y nuevas combinaciones de péptidos para inmunoterapia contra el cáncer de pulmón, incluido el cáncer de pulmón amicrocítico y otros tipos de cáncer | |
PE20181075A1 (es) | Nuevos pepticos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra la leucemia linfocitica cronica (llc) y otros tipos de cancer | |
CO2017012891A2 (es) | Péptidos y combinaciones de péptidos para la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer | |
CR20180001A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer. | |
CR20180245A (es) | Nuevos péptidos y combinación de péptidos para el uso en la inmunoterapia contra varios tipos de cáncer | |
CO2018000245A2 (es) | Péptidos y combinaciones de péptidos para inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer | |
CL2021002459A1 (es) | Péptidos y combinaciones de péptidos para uso en inmunoterapia contra el cáncer (divisional de la solicitud no. 201902093) | |
CO2019012077A2 (es) | Péptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cáncer | |
CL2018000545A1 (es) | Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. | |
CO2018004869A2 (es) | Péptidos y combinación de péptidos para inmunoterapia contra varios tipos de cáncer | |
CO2018012294A2 (es) | Inmunoterapia contra el melanoma y otros tipos de cáncer | |
CL2023001324A1 (es) | Péptidos, combinaciones, células para inmunoterapia contra cáncer de vejiga y otros cánceres | |
CL2020002935A1 (es) | Péptidos para el uso en la inmunoterapia contra el cáncer | |
CL2021001012A1 (es) | Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer microcítico de pulmón y otros tipos de cáncer (divisional de la solicitud no. 201800780) | |
CO2017009101A2 (es) | Péptidos y combinación de péptidos | |
CO2018006022A2 (es) | Epítopos celulares y combinaciones de epítopos celulares para inmunoterapia del mieloma y de otros tipos de cáncer |